Skip to content

South Africa awards antiretroviral supply contracts

Seroreversion possible, but rare, after early treatment of acute HIV infection

First randomised study of treatment in primary HIV infection begins recruitment

Stavudine and efavirenz in short supply for developing world, say manufacturers

AIDS events with a viral cause decline most steeply after starting HAART

HAART can be safely interrupted for over a year by patients with lowest ever CD4 cell count above 250 and a sustained treatment CD4 cell count of 500 or more

Pilot study suggests that Kaletra maintenance therapy safe

Small number of UK HIV-positive patients at risk of exhausting treatment options

'Dear Dr' letter issued about risks of using tenofovir and ddI together